{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:36:58Z","timestamp":1773297418140,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.diabres.2016.04.027","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T16:11:19Z","timestamp":1462032679000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"116","author":[{"given":"Sayuri","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2016.04.027_b0005","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.04.027_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.diabres.2016.04.027_b0015","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2016.04.027_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2016.04.027_b0025","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjmed.2009.03.015","article-title":"Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use","volume":"122","author":"Kendall","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2016.04.027_b0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0378-1119(96)00730-5","article-title":"Analysis of an expression profile of genes in the human adipose tissue","volume":"190","author":"Maeda","year":"1997","journal-title":"Gene"},{"key":"10.1016\/j.diabres.2016.04.027_b0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.diabres.2016.04.027_b0040","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/db10-1707","article-title":"Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome","volume":"60","author":"Lamers","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2016.04.027_b0045","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.2337\/dc13-0496","article-title":"Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro","volume":"36","author":"Sell","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.04.027_b0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trsl.2011.09.005","article-title":"Serum level of soluble CD26\/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and\/or sulfonylurea","volume":"159","author":"Aso","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.diabres.2016.04.027_b0055","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1210\/jc.2012-4288","article-title":"CD26\/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus","volume":"98","author":"Lee","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2016.04.027_b0060","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus","volume":"1","author":"Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2016.04.027_b0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4172\/2155-6156.1000416","article-title":"Pioglitazone increases serum DPP-4 level in type 2 diabetes mellitus","volume":"5","author":"Kanazawa","year":"2014","journal-title":"Journal of Diabetes & Metabolism"},{"key":"10.1016\/j.diabres.2016.04.027_b0070","unstructured":"Notsu M, Kanazawa I, Tanaka S, Yamaguchi T, Sugimoto T. Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus. Clin Endocrinol, Epub ahead of print."},{"key":"10.1016\/j.diabres.2016.04.027_b0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00198-010-1184-7","article-title":"Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus","volume":"22","author":"Kanazawa","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.diabres.2016.04.027_b0080","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2169\/naika.94.794","article-title":"The definition and criteria of metabolic syndrome","volume":"94","author":"The Examination Committee of Criteria for Metabolic syndrome","year":"2005","journal-title":"Nihon Naika Gakkai Zasshi (J Jpn Soc Int Med)"},{"key":"10.1016\/j.diabres.2016.04.027_b0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bone.2009.05.003","article-title":"Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes","volume":"45","author":"Yamaguchi","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.diabres.2016.04.027_b0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.2040-1124.2011.00156.x","article-title":"Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients","volume":"3","author":"Bando","year":"2012","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2016.04.027_b0095","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systemic review and meta-analysis","volume":"56","author":"Kim","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2016.04.027_b0100","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.2174\/092986711798184299","article-title":"Determinants of increased cardiovascular disease in obesity and metabolic syndrome","volume":"18","author":"Vazzana","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.diabres.2016.04.027_b0105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.metabol.2014.12.004","article-title":"Increased plasma DPP-4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation","volume":"64","author":"Zheng","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2016.04.027_b0110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.metabol.2014.06.004","article-title":"Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes","volume":"63","author":"Tremblay","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2016.04.027_b0115","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1002\/dme.1996.13.s6.7","article-title":"Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups","volume":"13","author":"Fujimoto","year":"1996","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2016.04.027_b0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0002-9440(10)62266-3","article-title":"Circulating CD26 is negatively associated with inflammation in human and experimental arthritis","volume":"166","author":"Busso","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.diabres.2016.04.027_b0125","first-page":"1858","article-title":"Reduction of serum soluble CD26\/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus","volume":"29","author":"Kobayashi","year":"2002","journal-title":"J Rheumatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T01:55:04Z","timestamp":1567821304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716300912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":25,"alternative-id":["S0168822716300912"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.04.027","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}